Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
HEMOPHILIA B
Interventions
DRUG

Benefix

"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."

Trial Locations (16)

100045

Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing

200025

Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine/Hematology Department, Shanghai

215006

Department of Hematology,The First Affiliated Hospital of Soochow University, Suzhou

221006

Department of Hematology,The Affiliated Hospital of Xuzhou Medical University, Xuzhou

250014

Blood Center of Shandong Province, Jinan

300020

Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology), Tianjin

330006

Department of Hematology,Jiangxi Provincial People's Hospital, Nanchang

400014

Children's Hospital of Chongqing Medical University, Chongqing

410008

Xiangya Hospital of Centre-South University, Changsha

430030

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan

450003

Henan Provincial People's Hospital, Zhengzhou

510515

Nanfang Hospital, Southern Medical University, Guangzhou

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

610073

Chengdu Women's and Children's Central Hospital, Chengdu

650032

Department of Hematology,The First Affiliated Hospital of Kunming Medical University, Kunming

030001

Shanxi Medical University Second Hospital, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02336178 - Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China | Biotech Hunter | Biotech Hunter